Skip to main content
SpringerLink
Log in

Post ASCO update 2014: head and neck cancer

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this short review is to summarize some of the most important abstracts relating to the field of head and neck cancer presented at the ASCO Annual Meeting 2014. An Italian study group presented the first randomized phase III trial showing improved survival for patients with locally advanced squamous carcinoma of the head and neck using induction chemotherapy as an add-on to definitive local chemoradiotherapy or radiotherapy plus cetuximab. As these data are in contrast to already published trials and many questions around this treatment strategy remain unanswered, the definitive place of sequential therapies within the treatment algorithms remains to be defined. With the phase Ib data on the therapeutic efficacy of the anti-PD-1 antibody pembrolizumab released at the ASCO meeting we now for the first time have clinical evidence that modern immunotherapeutic strategies are worth studying in head and neck cancer. Finally, the phase III SELECT trial establishing lenvatinib as another therapeutic option in the treatment of radioiodine-refractory thyroid cancer will be discussed. In this study the experimental compound was shown to improve response rate and progression free survival with an acceptable toxicity profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gregoire V, Lefebvre JL, Licitra L, Felip E, et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;2(Suppl 5):v184–6.

  2. Fabregas JC, Loaiza-Bonilla A, Talebi TN, et al. Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. Expert Rev Anticancer Ther. 2013;13(9):1065–72.

    Article  CAS  PubMed  Google Scholar 

  3. Haddad R, O’Neill AO, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomized phase 3 trial. Lancet Oncol. 2013;14(3):257–64.

    Article  CAS  PubMed  Google Scholar 

  4. Hitt R, Grau JJ, Lopez-Pousa A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25:216–25.

    Article  CAS  PubMed  Google Scholar 

  5. Cohen EEW, Karrison TG, Kocherginsky M, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735–43.

    Article  CAS  PubMed  Google Scholar 

  6. Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-flourouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol. 2014;32:5s (abstract 6004).

    Article  Google Scholar 

  7. Hanna GJ, Haddad RI, Lorch JH. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013;18:288–93.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Ma J, Liu Y, Huang X, et al. Induction chemotherapy decreases the rate of distant metastases in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta analysis. Oral Oncol. 2012;48:1076–84.

    Article  CAS  PubMed  Google Scholar 

  9. LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.

    Article  Google Scholar 

  10. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300–9.

    Article  CAS  PubMed  Google Scholar 

  12. Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cancer and prostate cancer. Curr Oncol Rep. 2013;15:98–104.

    Article  CAS  PubMed  Google Scholar 

  13. Champiat S, Ileana E, Giaccone G, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thor Oncol. 2014;9:144–53.

    Article  CAS  Google Scholar 

  14. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733–41.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Tsushima F, Tanaka K, Otsuki N, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006;42:268–74.

    Article  CAS  PubMed  Google Scholar 

  16. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol. 2014;32:5s (abstract 6011).

    Article  Google Scholar 

  17. Anderson RT, Linnehan JE, Tongbram V, et al. Clinical, safety and economic evidence in radioactive-iodine refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013;23:392–407.

    Article  CAS  PubMed  Google Scholar 

  18. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive-iodine refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–28.

    Article  CAS  PubMed  Google Scholar 

  19. Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitarget kinase inhibitor E7080 in advanced radioiodine (RAI) refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011;29 (abstract 5503).

  20. Schlumberger M, Tahara M, Wirth LJ, et al. A phase 3, multicentre, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol. 2014;32:5s (abstract LBA6008).

    Article  Google Scholar 

Download references

Conflict of interest

The author has received honoraria for advisory-board participation from Bayer Healthcare.

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, Hematology/Oncology, University Hospital Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria

    Georg Pall MD

Authors
  1. Georg Pall MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georg Pall MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pall, G. Post ASCO update 2014: head and neck cancer. memo 7, 231–236 (2014). https://doi.org/10.1007/s12254-014-0183-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0183-3

Keywords

Search

Navigation